3. Results
diabetes
DIABETES
A total of 1.163 patients were randomized into the control (Baseline parameters did not differ significantly between groups with the exception of a lower baseline HbAMoreover, baseline characteristics of completers and drop-outs did not significantly differ, except for group assignment, diabetes duration, and body weight, i.e., subjects in the control group (A treatment superiority was observed for the TeLIPro group with an ETD in HbAWhile in the control group of patients with diabetes duration ≥ 5 years there was no significant improvement of HbAAlthough not reaching a statistically significant difference, the HbAThe responder analysis showed that the RR for a clinically relevant reduction in HbA1c of at least 0.5% was significantly higher in the TeLIPro group after 12 months (RR 1.9 [1.3; 3.0], Although there was no significant difference in RR of achieving HbAMoreover, significant treatment priority for body weight, BMI, physical and mental wellbeing, impairment of quality of life, and eating behaviour was observed for the TeLIPro group compared to the control group after 12 months of intervention (